Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 6/20 | 0.45 |
| ▸ | CA1 | P00915 | 6/20 | 0.45 |
| ▸ | CA2 | P00918 | 6/20 | 0.45 |
| ▸ | CA9 | Q16790 | 4/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA5A | P35218 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15198257 | 1.00 | LMNA (0.54) | LMNAALDH1A1POLBCA12CA1 | |
| SCHEMBL15198243 | 1.00 | LMNA (0.54) | LMNAALDH1A1POLBCA12CA1 | |
| SCHEMBL15700875 | 1.00 | LMNA (0.54) | LMNAALDH1A1POLBCA12CA1 | |
| SCHEMBL15198251 | 0.93 | LMNA (0.56) | LMNAALDH1A1POLBCA12CA1 | |
| SCHEMBL10109164 | 0.93 | LMNA (0.56) | LMNAALDH1A1POLBCA12CA1 | |
| SCHEMBL15198269 | 0.92 | LMNA (0.58) | LMNAALDH1A1POLBCA12CA1 | |
| SCHEMBL10109474 | 0.92 | LMNA (0.58) | LMNAALDH1A1POLBCA12CA1 | |
| SCHEMBL15700845 | 0.92 | LMNA (0.58) | LMNAALDH1A1POLBCA12CA1 | |
| SCHEMBL10109451 | 0.87 | LMNA (0.60) | LMNAALDH1A1POLBCA12CA1 | |
| SCHEMBL10109103 | 0.87 | LMNA (0.60) | LMNAALDH1A1POLBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | NuTek Pharma Ltd. | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022012-A1 | Glycosylated Acetaminophen Pro-Drug Analogs | UGT1A3, GCG, UGT1A1 | LMNA 1396/4885ALDH1A1 282/4885POLB 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.